Ibalizumab

Feb 27, 2019

WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

Feb 18, 2019

EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics

Jan 25, 2019

Global HIV Competitor Landscape Report 2018: Timeline Forecasts for Each Approved Product's Lifecycle Management Initiatives

Mar 06, 2018

FDA approves new HIV treatment for patients who have limited treatment options

Mar 06, 2018

Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo(TM) (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1

Mar 06, 2018

WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo

Aug 02, 2017

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics cGMP Manufacturing Facilities for Production of TMB-355 (ibalizumab)